“dasatinib”

“dasatinib”

Dasatinib is a prescription medicine that blocks certain enzymes called tyrosine kinases, which cells use to send growth and survival signals. By interfering with those signals, it can slow or stop the growth of some cancer cells. Doctors most commonly use it to treat certain blood cancers, especially chronic myeloid leukemia and some forms of acute lymphoblastic leukemia that carry a specific abnormal protein. It is taken as a daily pill and is considered a targeted therapy because it aims at particular molecular drivers of disease rather than all rapidly dividing cells. In research settings, dasatinib has also been shown to help eliminate old, dysfunctional cells called senescent cells when given with other compounds, which has generated interest for potential uses beyond cancer. That experimental activity has led scientists to explore whether it could help reduce age-related tissue damage and improve healing in certain conditions. Despite its promise, dasatinib can cause significant side effects such as low blood counts, fluid retention, bleeding, and changes in heart function, so patients need close medical monitoring. It also interacts with many other medicines, so full disclosure of supplements and other drugs to the treating clinician is important. Because it affects key cell signaling pathways, dasatinib should be used only under specialist supervision and with careful follow-up. Overall, it matters because it shows how targeting specific molecular faults can improve treatment precision and open new avenues for treating disease and possibly aspects of aging.